Immunosuppressive Effects of Beta-herpesviruses

Herpes

Volumn 10, Issue 1, 2003, Pages 12-16

  Boeckh, Michael ^a,b   Nichols, W Garrett ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cytomegalovirus (CMV); Graft rejection; Hepatitis C; HIV; Human herpesvirus type 6 (HHV 6); Human herpesvirus type 7 (HHV 7); Immunomodulation; Immunosuppressive effects

Indexed keywords

BACTERIAL INFECTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; DISEASE SEVERITY; GRAFT REJECTION; HEPATITIS C VIRUS; HERPES; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNOMODULATION; INCIDENCE; INFECTION RISK; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; BETAHERPESVIRINAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HERPES VIRUS INFECTION; HUMAN; RANDOMIZED CONTROLLED TRIAL; TRANSPLANTATION;

BACTERIA (MICROORGANISMS); CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HEPATITIS C VIRUS; HERPESVIRIDAE; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

VIRUS VACCINE;

BETAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTATION; VIRAL VACCINES;

EID: 0037865498     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. George ML, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Cytogam, MedImmune, Inc., Gaithersburg, Maryland. Am J Med 1997;103:106-113.
2. Razonable RR, Burak KW, van Cruijsen H, Brown RA, Charlton MR, Smith TF et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Inject Dis 2002;35:974-981.
3. Broers AE, van Der Holt R, van Esser JW, Gratama JW, Henzen-Logmans S, Kuenen-Boumeester V et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000;95:2240-2245.
4. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002;185:273-282.
5. Pleskoff O, Treboute C, Brelot A, Heveker N, Seman M, Alizon M. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 1997;276:1874-1878.
6. Robain M, Boufassa F, Hubert JB, Persoz A, Burgard M, Meyer L. Cytomegalovirus seroconversion as a cofactor for progression to AIDS. AIDS 2001;15:251-256.
7. Sabin CA, Devereux HL, Clewley G, Emery VC, Phillips AN, Loveday C et al. Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. J Infect Dis 2000;181:1800-1803.
8. Leach CT, Detels R, Hennessey K, Liu Z, Visscher BR, Dudley JP et al. A longitudinal study of cytomegalovirus infection in human immunodeficiency virus type 1-seropositive homosexual men: molecular epidemiology and association with disease progression. J Infect Dis 1994;170:293-298.
9. Mostad SB, Kreiss JK, Ryncarz AJ, Overbaugh J, Mandaliya K, Chohan B et al. Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. J Med Virol 1999;59:469-473.
10. Speck CE, Coombs RW, Koutsky LA, Zeh J, Ross SO, Hooton TM et al. Risk factors for HIV-1 shedding in semen. Am J Epidemiol 1999;150:622-631.
11. Spector SA, Wong R, Hsia K, Pilcher M, Stempien MJ. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. J Clin Invest 1998;101:497-502.
12. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-1470.
13. Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998;26:1076-1082.
14. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ et al. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002;169:1984-1992.
15. Randolph-Habecker J, Iwata M, Torok-Storb B. Cytomegalovirus mediated myelosuppression. J Clin Virol 2002;25(Suppl 2):51.
16. Kapasi K, Rice GP. Cytomegalovirus infection of peripheral blood mononuclear cells: effects on interleukin-1 and -2 production and responsiveness. J Virol 1988;62:3603-3607.
17. Schrier RD, Oldstone MB. Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity. J Virol 1986;59:127-131.
18. Schrier RD, Rice GP, Oldstone MB. Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis 1986;153:1084-1091.
19. Jones TR, Sun L. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol 1997;71:2970-2979.
20. Tomazin R, Boname J, Hegde NR, Lewinsohn DM, Altschuler Y, Jones TR et al. Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells. Nat Med 1999;5:1039-1043.
21. Ng-Bautista CL, Sedmak DD. Cytomegalovirus infection is associated with absence of alveolar epithelial cell HLA class II antigen expression. J Infect Dis 1995;171:39-44.
22. Hopkins HA, Monick MM, Hunninghake GW. Cytomegalovirus inhibits CD14 expression on human alveolar macrophages. J Infect Dis 1996;174:69-74.
23. Kapasi K, Rice GP. Role of the monocyte in cytomegalovirus-mediated immunosuppression in vitro. J Infect Dis 1986;154:881-884.
24. Miller SA, Bia FJ, Coleman DL, Lucia HL, Young KR, Jr, Root RK. Pulmonary macrophage function during experimental cytomegalovirus interstitial pneumonia. Infect Immun 1985;47:211-216.
25. Span AH, Van Boven CP, Bruggeman CA. The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells. Eur J Clin Invest 1989;19:542-548.
26. Sparrelid E, Emanuel D, Fehniger T, Andersson U, Andersson J. Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T cell-mediated cytotoxicity. Transplantation 1997;63:1782-1789.
27. Cenci E, Perito S, Enssle KH, Mosci P, Latge JP, Romani L et al. Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun 1997;65:564-570.
28. Cenci E, Mencacci A, Fe d'Ostiani C, DeI Sero G, Mosci P, Montagnoli C et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998;178:1750-1760.
29. Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 2000;97:1695-1700.
30. Lockridge KM, Zhou SS, Kravitz RH, Johnson JL, Sawai ET, Blewett EL et al. Primate cytomegaloviruses encode and express an IL-10-like protein. Virology 2000;268:272-280.
31. Clark DA. Human herpesvirus 6. Rev Med Virol 2000;10:155-173.
32. Okuno T, Takahashi K, Balachandra K, Shiraki K, Yamanishi K, Takahashi M et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 1989;27:651-653.
33. Cone RW, Hackman RC, Huang ML, Bowden RA, Meyers JD, Metcalf M et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993;329:156-161.
34. Dockrell DH. Human herpesvirus 6: molecular biology and clinical features, J Med Microbiol 2003;52:]5-18.
35. Santoro F, Kennedy PE, Locatelli G, Malnati MS, Berger EA, Lusso P. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999;99:817-827.
36. Lusso P, Malnati M, De Maria A, Balotta C, DeRocco SE, Markham PD et al. Productive infection of CD4+ and CD8+ mature human T cell populations and clones by human herpesvirus 6. Transcriptional down-regulation of CD3. J Immunol 1991;147:685-691.
37. Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J. Immunosuppressive effect of human herpesvirus 6 on T-cell functions: suppression of interleukin-2 synthesis and cell proliferation. Blood 1995;85:1263-1271.
38. Flamand L, Gosselin J, D'Addario M, Hiscott J, Ablashi DV, Gallo RC et al. Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol 1991;65:5105-5110.
39. Li C, Goodrich JM, Yang X. Interferon-gamma (IFN-gamma) regulates production of IL-10 and IL-12 in human herpesvirus-6 (HHV-6)-infected monocyte/macrophage lineage. Clin Exp Immunol 1997;109:421-425.
40. Flamand L, Stefanescu I, Menezes J. Human herpesvirus-6 enhances natural killer cell cytotoxicity via IL-15. J Clin Invest 1996;97:1373-1381.
41. Hasegawa H, Utsunomiya Y, Yasukawa M, Yanagisawa K, Fujita S. Induction of G protein-coupled peptide receptor EBI 1 by human herpesvirus 6 and 7 infection in CD4+ T cells. J Virol 1994;68:5326-5329.
42. Ljungman P, Wang FZ, Clark DA, Emery VC, Remberger M, Ringden O et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000;111:774-781.
43. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119-126.
44. Soderberg-Naucler C, Fish KN, Nelson JA. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J Clin Invest 1997;100:3154-3163.
45. Fietze E, Prosch S, Reinke P, Stein J, Docke WD, Staffa G et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994;58:675-680.
46. Wang FZ, Larsson K, Linde A, Ljungman P. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2002;30:521-526.
47. Kositanont U, Wasi C, Wanprapar N, Bowonkiratikachorn P, Chokephaibulkit K, Chearskul S et al. Primary infection of human herpesvirus 6 in children with vertical infection of human immunodeficiency virus type 1. J Infect Dis 1999;180:50-55.
48. Dockrell DH, Prada J, Jones MF, Patel R, Badley AD, Harmsen WS et al. Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 1997;176:1135-1140.
49. Humar A, Malkan G, Moussa G, Greig P, Levy G, Mazzulli T. Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. J Infect Dis 2000;181:1450-1453.
50. Buchbinder S. Elmaagacli AH, Schaefer UW, Roggendorf M. Human herpesvirus 6 is an important pathogen in infectious lung disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;26:639-644.
51. Singh N, Husain S, Carrigan DR, Knox KK. Weck KE, Wagener MM et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002;16:92-96.
52. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002;2:461-466.
53. Osman HK, Peiris JS, Taylor CE, Warwicker P. Jarrett RF, Madeley CR. 'Cytomegalovirus disease' in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? J Med Viral 1996;48:295-301.
54. Kidd IM, Clark DA, Sabin CA. Andrew D, Hassan-Walker AF, Sweny P et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000;69:2400-2404.
55. Tong CY, Bakran A, Williams H, Cheung CY, Peiris JS. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000;70:213-216.
56. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001;183:179-184.
57. Emery VC. Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis 2001;32:1357-1360.
58. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994;343:749-753,
59. Cooper DA, Pehrson PO, Pedersen C, Moroni M, Oksenhendler E, Rozenbaum W et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial, European-Australian Collaborative Group. AIDS 1993;7:197-207.
60. Youle MS, Gazzard BG, Johnson MA, Cooper DA, Hoy JF, Busch H et al. Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. European-Australian Acyclovir Study Group. AIDS 1994;8:641-649.
61. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.